How to bid on the NCI SBIR Innovative Concept Phase I Award Program

What the NCI is buying and why it matters to you

The National Cancer Institute (NCI) is seeking research proposals from small businesses for its Phase I Small Business Innovation Research (SBIR) Innovative Concept Award Program. This program aims to support high-risk, high-reward research and development (R&D) of new technologies to benefit cancer patients, providers, and caregivers.

Specifically, NCI is looking for proposals in two main areas: developing therapeutic or preventative technologies for pediatric and rare cancers, and creating devices, diagnostic technologies, or digital health tools for the treatment, detection, and diagnosis of pediatric and rare cancers. For rare cancers, those with a five-year survival rate of less than 50% are particularly encouraged. This is an opportunity for small businesses to secure funding for innovative, early-stage cancer technology development.

Key dates and what happens at the deadline

The solicitation was published on August 10, 2026. All proposals must be submitted by the deadline of September 21, 2026, at 5:00 PM ET. It is important to note that this deadline has remained unchanged despite amendments to the solicitation.

At the deadline, your complete proposal, including a signed copy of the SF30 Amendment (page 1 only), must be received by the NCI. Late submissions will not be considered. The NCI is not obligated to make any awards and is not responsible for any costs incurred by offerors before a contract is awarded.

Who this opportunity suits

This opportunity is ideal for small business concerns with capabilities in health-related research and development, particularly those focused on cancer technologies. Firms that can conduct R&D and commercialize the results are encouraged to participate.

The program is designed for innovative concepts, meaning preliminary data is not required. However, proposals must demonstrate a sound scientific premise, identify an anticipated product, clearly outline the development path, and propose experiments to obtain initial de-risking and proof-of-concept data. Non-exempt human subjects research will not be supported under this solicitation.

How to respond to this solicitation

To access the full solicitation details and prepare your response, you will need to view the original source on the portal. Click the “View original source” link. If the first click takes you to the portal’s homepage, click it again to go directly to the bid.

You may need to create a free account on the portal to view all attached documents, including Amendment #3 which provides key questions and answers. Remember to submit a signed copy of the SF30 Amendment (page 1 only) with your Business Proposal.

Practical tips for a competitive response

Even though preliminary data is not required, clearly articulate the scientific basis for your proposed idea. Reference existing literature or your own foundational research to establish a strong scientific premise. This will demonstrate the viability of your concept.

Focus on defining a clear product path. Your proposal should not just be about research; it needs to show how the R&D will lead to a tangible product. Clearly identify the clinical problem and the specific cancer type(s) your proposal addresses, with adequate justification.

Propose well-defined experiments for initial de-risking and proof-of-concept. Outline the specific activities you will undertake in Phase I to demonstrate feasibility. This shows the NCI you have a concrete plan to move your innovative concept forward.